1. Introduction
===============

Physical activity (PA) is any bodily movement produced by skeletal muscles that requires energy expenditure \[[@B1-ijms-15-12407]\]. It includes exercise as well as work and recreational activities which involve bodily movements. PA can be quantified by metabolic equivalent task (MET) intensity \[[@B1-ijms-15-12407],[@B2-ijms-15-12407]\], and plays an important role in the morbidity, mortality, and health care costs of obesity and related chronic diseases \[[@B3-ijms-15-12407]\].

The behavior of PA may be determined by genetic factors \[[@B4-ijms-15-12407],[@B5-ijms-15-12407],[@B6-ijms-15-12407]\]. In particular, between 48% and 71% of the variability in adult exercise behavior can be explained by genetic factors \[[@B6-ijms-15-12407]\]. Indeed, evidence from twin and family studies have suggested that genetic factors contribute to the propensity of being sedentary \[[@B5-ijms-15-12407]\]. A novel approach has been proposed to identify genetic variants that are related to leisure-time exercise behavior, by conducting Genome-Wide Association (GWA) analyses using logistic regression to find genes associated with exercisers and non-exercisers \[[@B7-ijms-15-12407]\]. Recently, a genome-wide study with quantitative PA as a phenotype was performed for the Korean population \[[@B8-ijms-15-12407]\]. This study revealed how to define phenotypes of PA in genetic association studies, together with appropriate statistical methods for their analysis \[[@B8-ijms-15-12407]\].

In reporting genetic variants associated with a trait or disease, most traditional GWA studies adopted a single-marker approach that identifies single genetic factors one by one. However, this method is inefficient in predicting joint effects of multiple genetic variants on the common complex trait \[[@B9-ijms-15-12407],[@B10-ijms-15-12407]\]. A multiple-marker approach is the preferred alternative for their joint identification \[[@B11-ijms-15-12407]\]. However, multiple linear and logistic regression models are often ill-defined in GWA studies when the number of predictor variables is larger than the sample size. In addition, collinearity often occurs between predictor variables due to linkage disequilibrium among single nucleotide polymorphisms (SNPs).

To identify multiple genetic variants for common complex traits or diseases, an elastic-net (EN) regularization method had been proposed by Cho *et al.* \[[@B11-ijms-15-12407]\], along with some consistency measures based on bootstrap sampling. The EN regularization method was originally introduced for model fitting and variable selection in ill-defined multiple regressions. It has been applied to GWA studies \[[@B12-ijms-15-12407],[@B13-ijms-15-12407]\] and provided a better prediction than those based on ordinary regression models \[[@B14-ijms-15-12407],[@B15-ijms-15-12407]\] when variables are larger than sample sizes and multicollinearity problems may exist.

The present study aimed to find genetic variants influencing PA in the Korean population. Single-SNP association tests were initially conducted to assess genetic associations between daily PA and various SNP markers. We then performed multiple SNP analysis with EN regularization to determine genetic variants associated with PA. The SNPs identified provide novel biological evidence to understand the genetics of PA through pathway enrichment analysis.

2. Results and Discussion
=========================

2.1. Results
------------

### 2.1.1. Physical Activity Levels

Overall, the average daily PA level was 1332 (SD 871) MET·min for the Korean participants. Men (mean 1367, SD 887 MET·min·day^−1^) appeared to be slightly more active than women (mean 1300, SD 856 MET·min·day^−1^). The mean PA level of the Ansung cohort (1678, SD 1046 MET·min·day^−1^) was higher than that of the Ansan cohort (1038, SD 534 MET·min·day^−1^), suggesting that people in the rural community tended to be more active than their city counterparts. [Figure 1](#ijms-15-12407-f001){ref-type="fig"} shows the box plots of self-reported PA by age groups (40--44, 45--49, 50--54, 55--59, 60--64, 65+). Although the median PA levels of these six age groups were similar, the PA distributions exhibited substantial variations. In particular, the majority of younger participants appeared to sustain low PA levels with the exception of a few outliers. For older participants especially those over 65 years, their PA levels varied considerably between individuals, as evident from the wide interquartile ranges.

![Box plots of total amount of physical activity (PA) by age group (40--44, 45--49, 50--54, 55--59, 60--64, 65+).](ijms-15-12407-g001){#ijms-15-12407-f001}

### 2.1.2. Individual Single Nucleotide Polymorphism (SNP)-Based Association Analysis

Single-marker association analysis was performed for individual SNP with sex, age, area, and body mass index as covariates. [Table 1](#ijms-15-12407-t001){ref-type="table"} presents the results of the single-SNP association tests. The first six columns give the SNP information and the remaining columns summarize the regression results. [Figure 2](#ijms-15-12407-f002){ref-type="fig"} further shows the Manhattan plot of 344,893 SNPs, where the *y*-axis represents the log-transformed *p*-value and the *x*-axis represents the chromosomes. The horizontal solid line indicates *p*-value = 10^−5^. Although these SNPs did not achieve the genome-wide level significance, 41 genetic variants (listed in [Table 1](#ijms-15-12407-t001){ref-type="table"}) emerged among the 344,893 SNPs to have some evidence of association with PA under *p*-value \< 10^−4^, and they were mapped to 27 genes.

![Manhattan plot showing total amount of PA. The horizontal reference line represents the genome-wide association (GWA) threshold *p*-values 10^−5^. The *p*-values from single SNP association test is indicated in −log~10~ scale against each chromosome.](ijms-15-12407-g002){#ijms-15-12407-f002}

ijms-15-12407-t001_Table 1

###### 

Single nucleotide polymorphisms (SNPs) associated with physical activity by single-SNP association tests (*p*-value \< 10^−4^).

  rs Number    Gene Symbol                  Location of SNP       Cytoband    Minor Allele   MAF ^a^   BETA ^b^   *p*-Value ^c^
  ------------ ---------------------------- --------------------- ----------- -------------- --------- ---------- ---------------
  rs7023003    *RN7SK*, *SLC44A1*           intergenic            9q31.1d     G              0.2522    65.58      4.67 × 10^−5^
  rs11791649                                intergenic            9q31.1b     A              0.0681    107.6      1.30 × 10^−5^
  rs6074898    *MACROD2*                    intronic              20p12.1c    C              0.0598    113.9      1.42 × 10^−5^
  rs17228531                                intergenic            9q31.1b     A              0.0676    107.1      1.49 × 10^−5^
  rs10057067   *ITGA1*                      intronic              5q11.2b     G              0.4550    −53.42     1.67 × 10^−5^
  rs12462609   *CACNA1A*                    intronic              19p13.13b   A              0.1120    −83.29     2.04 × 10^−5^
  rs7020422    *RN7SK, SLC44A1*             intergenic            9q31.1d     A              0.2350    61.84      2.59 × 10^−5^
  rs11952141                                intergenic            5p15.1a     C              0.1833    67.73      2.92 × 10^−5^
  rs6867384                                 intergenic            5p15.1a     G              0.1838    67.28      3.18 × 10^−5^
  rs6891956                                 intergenic            5p15.1a     T              0.1839    66.67      3.66 × 10^−5^
  rs6880596                                 intergenic            5p15.1a     A              0.1767    67.66      3.78 × 10^−5^
  rs17069951   *CITED2*                     intergenic            6q24.1b     T              0.0106    246.8      3.91 × 10^−5^
  rs10507652   *TDRD3*                      intergenic            13q21.2b    T              0.0536    −113.1     3.95 × 10^−5^
  rs11781985   *MFHAS1*, *CLDN23*           intergenic            8p23.1d     C              0.0632    105.8      4.23 × 10^−5^
  rs940031     *CLDN23*                     intergenic            8p23.1d     T              0.0822    92.64      4.31 × 10^−5^
  rs11586310   *IRF2BP2*                    intergenic            1q42.3a     G              0.0625    −104.3     4.38 × 10^−5^
  rs2519580    *TFPI2*                      intergenic            7q21.3a     T              0.1466    −71.32     4.62 × 10^−5^
  rs2519573    *TFPI2*                      intergenic            7q21.3a     T              0.1469    −71.19     4.69 × 10^−5^
  rs2724079    *TFPI2*                      intergenic            7q21.3a     A              0.1475    −70.25     5.77 × 10^−5^
  rs11783707   *MFHAS1,CLDN23*              intergenic            8p23.1d     T              0.0627    103.9      6.10 × 10^−5^
  rs2093145    *CST9*                       intergenic            20p11.21b   A              0.2963    −54.71     6.10 × 10^−5^
  rs1888286    *ASTN2*                      intronic              9q33.1b     G              0.3201    53.33      6.51 × 10^−5^
  rs11587639   *IRF2BP2*                    intergenic            1q42.3a     C              0.0608    −103.2     6.72 × 10^−5^
  rs11780486   *MFHAS1*, *CLDN23*           intergenic            8p23.1d     C              0.0625    103.4      6.74 × 10^−5^
  rs337999     *GALNT17*                    intronic              4q34.1b     G              0.2463    57.03      6.83 × 10^−5^
  rs2987460    *IRF2BP2*                    intergenic            1q42.3a     T              0.0727    −94.17     7.74 × 10^−5^
  rs337997     *GALNT17*                    intronic              4q34.1b     T              0.2458    56.61      7.82 × 10^−5^
  rs853334     *FGD5*, *C3ORF20*            intergenic            3p24.3e     A              0.4373    −49.31     7.92 × 10^−5^
  rs11111767   *NT5DC3*                     intronic              12q23.3a    A              0.3923    49.77      8.12 × 10^−5^
  rs7083122    *RHOBTB1*                    intronic              10q21.2a    A              0.1486    68.83      8.67 × 10^−5^
  rs1928980    *ASTN2*                      intronic              9q33.1b     A              0.3152    52.4       8.76 × 10^−5^
  rs2421930    *DDX18*                      intergenic            2q14.1d     G              0.0290    147        8.77 × 10^−5^
  rs1928984    *ASTN2*                      intronic              9q33.1b     C              0.3157    52.33      8.81 × 10^−5^
  rs3751204    *NT5DC3*                     utr-variant-3-prime   12q23.3a    T              0.3783    49.85      8.86 × 10^−5^
  rs10124001   *JAK2*, *RCL1*, *MIR101-2*   intergenic            9p24.1c     A              0.1146    −76.5      9.19 × 10^−5^
  rs1265074    *CCHCR1*                     intronic              6p21.33a    A              0.3225    −51.96     9.23 × 10^−5^
  rs2493869    *CDKAL1*                     intronic              6p22.3b     A              0.3373    −51.44     9.39 × 10^−5^
  rs10495350   *IRF2BP2*                    intergenic            1q42.3a     T              0.0613    −100.4     9.45 × 10^−5^
  rs2446484    *CDKAL1*                     intronic              6p22.3b     G              0.3213    −51.99     9.66 × 10^−5^
  rs10989864                                intergenic            9q31.1b     A              0.0428    117.6      9.94 × 10^−5^
  rs4344422    *ADRA2A*                     intergenic            10q25.2b    G              0.0910    83.98      1.00 × 10^−4^

^a^ MAF stands for Minor allele frequency; ^b^ Coefficient from single-marker association test with age, sex, area, and body mass index included as covariates; ^c^ *p*-values from single-marker association test indicates *p*-value = 10^−5^. Although these SNPs did not achieve the genome-wide level significance, 41 genetic variants (listed in [Table 1](#ijms-15-12407-t001){ref-type="table"}) emerged among the 344,893 SNPs to have some evidence of association with PA under *p*-value \< 10^−4^, and they were mapped to 27 genes.

### 2.1.3. Multiple SNP-Based Association Analysis

The multi-stage procedure was applied to identify multiple causal SNPs. After performing single-SNP association tests in the first stage, we chose top 1000, top 2000, top 3000, and top 4000 SNPs that exhibit the strongest individual associations with PA. During the next stage, 639, 1248, 1760, and 2239 from the respective top SNP groups were jointly identified as PA-related genetic variants by the EN regularization method. The elastic-net allows correlation among predictors in variable selection, so there can be different selection results according to pre-screened datasets \[[@B11-ijms-15-12407]\]. At the validation stage, these jointly identified SNPs were further evaluated using the bootstrap selection stability (BSS) measure. Since the lists of SNPs were different depending on the number of pre-screened SNPs, we focused on the common 457 SNPs that were simultaneously identified from all four groups. These commonly selected variants have higher BSS than the variants which are chosen only one pre-defined dataset \[[@B11-ijms-15-12407]\]. [Table 2](#ijms-15-12407-t002){ref-type="table"} lists the final 59 variants selected with BSS ≥0.95 and mapped to 76 known genes. The *p*-values were calculated using a multiple linear regression model with adjustment for sex, age, area, and body mass index. Finally, pathway analysis found one pathway enriched in these 76 genes: Maturity onset diabetes of the young (MODY). This pathway includes *GCK* and *HES1* genes and has a *p*-value of 0.076.

ijms-15-12407-t002_Table 2

###### 

SNPs associated with physical activity with bootstrap selection stability (BSS) ≥95% in top 1000, top 2000, top 3000, and top 4000 SNPs through a multi-stage approach.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  rs Number    Gene Symbol                      Location of SNP        Cytoband    Minor Allele   MAF ^a^   Effect Size (4000) ^b^   BSS (4000) ^c^   *p*-Value ^d^ (4000)
  ------------ -------------------------------- ---------------------- ----------- -------------- --------- ------------------------ ---------------- ----------------------
  rs10849033   CCND2, C12ORF5                   intronic               12p13.32a   C              0.4886    19.799                   99.7             0.00003

  rs4252821    CCNI                             Downstream (500 bp)\   4q21.1b     G              0.1013    15.281                   96.9             0.00003
                                                Upstream (5000 bp)                                                                                    

  rs853334     FGD5, C3ORF20                    intronic               3p24.3e     A              0.4373    −15.166                  98.3             0.00009

  rs17099857   ARHGAP26                         intergenic             5q31.3e     C              0.0763    16.107                   99.2             0.00010

  rs4906747    ATP10A                           intergenic             15q12a      G              0.0640    14.613                   97.4             0.00010

  rs6030844    RNU6-1, RNU6-2                   intergenic             20q13.11b   C              0.1729    14.352                   97.6             0.00010

  rs10978130   PTPRD                            intergenic             9p23d       C              0.1523    23.022                   99.9             0.00013

  rs10507652   TDRD3                            intergenic             13q21.2b    T              0.0536    −19.779                  99.9             0.00015

  rs7649230    HES1                             intergenic             3q29c       C              0.3382    12.115                   96.4             0.00017

  rs13106655   TMEM156                          nonsynonymous          4p14c       G              0.2674    13.811                   98.2             0.00018

  rs16953182   UNC13C                           intronic               15q21.3b    G              0.0165    17.941                   99.2             0.00021

  rs7976955    VWF, TMEM16B                     utr-variant-3-prime    12p13.31e   T              0.0230    12.674                   95.5             0.00025

  rs2586038    MRPS23                           intergenic             17q22d      G              0.3314    −14.089                  97.1             0.00026

  rs9833833    UBE2E1                           intergenic             3p24.3a     T              0.3393    16.227                   99.3             0.00031

  rs41455146   ADAM12                           intergenic             10q26.2a    G              0.0726    −12.430                  96.5             0.00033

  rs2314612    GPR149, MME                      intronic               3q25.2c     A              0.4665    −20.284                  99.6             0.00033

  rs10513868   DLGAP1, FLJ35776                 intronic               18p11.31e   G              0.2335    13.314                   97.6             0.00035

  rs4131468    MBD2, DCC, SNORA30, SNORA37      intergenic             18q21.2c    T              0.4954    −15.354                  98.8             0.00036

  rs2851651                                     intergenic             11q22.1a    T              0.2047    −15.510                  99               0.00039

  rs2728504    ZNF521                           intergenic             18q11.2d    T              0.2713    −19.259                  96.9             0.00042

  rs17339892   MCTP1                            intergenic             5q15c       T              0.1076    12.451                   96.6             0.00051

  rs7997236    FAM155A                          intergenic             13q33.3a    A              0.0498    −20.321                  99.7             0.00054

  rs1387243    FAR2, RN5S1, CCDC91              intergenic             12p11.22b   C              0.1766    12.015                   98.4             0.00056

  rs707586     AJAP1                            intergenic             1p36.31b    G              0.2672    −18.571                  99.7             0.00064

  rs4978521    ZFP37, SLC46A2                   intergenic             9q32b       T              0.0886    −19.155                  96.7             0.00066

  rs2067730    NRXN3                            utr-variant-3-prime    14q31.1a    C              0.0308    −11.340                  96.2             0.00072

  rs16967978   LOC100132540, LOC339047, XYLT1   intronic               16p12.3c    A              0.0427    13.550                   95.2             0.00073

  rs41351947   EIF2B3                           intergenic             1p34.1d     C              0.0291    −15.446                  99.2             0.00073

  rs931701     BOC                              intronic               3q13.2b     A              0.3798    −15.920                  98.9             0.00077

  rs729239     RNU6-1, RNU6-2                   intronic               4q21.1b     T              0.0194    −15.186                  98.4             0.00080

  rs10020466   RN5S1                            intronic               4q34.3d     C              0.0739    −13.149                  98.4             0.00082

  rs1536053    C13ORF16                         intronic               13q34b      T              0.0393    −15.016                  96.8             0.00083

  rs17553316   RGNEF                            intergenic             5q13.2c     G              0.0192    12.629                   96.7             0.00094

  rs445942     C7ORF10, INHBA                   intronic               7p14.1b     C              0.1666    −16.716                  99               0.00099

  rs17058450   FAM116A                          intergenic             3p14.3a     T              0.0742    −12.336                  96.1             0.00103

  rs11167061   FLJ43860                         Upstream (5000 bp)     8q24.3d     A              0.2238    −15.508                  99.2             0.00112

  rs1453282                                     intronic               7p12.3b     C              0.3057    −16.260                  99.5             0.00130

  rs4864029    RNU6-1, RNU6-2                   intergenic             4q28.3b     G              0.1181    17.370                   99.4             0.00134

  rs4620043    LIFR                             intergenic             5p13.1c     A              0.2291    11.716                   95.3             0.00153

  rs2140340    CSMD1                            intronic               8p23.2c     T              0.0826    15.130                   98.4             0.00177

  rs3738178    MOSC1                            intergenic             1q41d       A              0.0966    13.128                   96.3             0.00189

  rs7770227                                     intergenic             6q22.1b     T              0.0781    18.199                   99.7             0.00192

  rs17730347   MCTP2                            intronic               15q26.2a    C              0.2599    13.531                   96.4             0.00194

  rs11024787   PTPN5                            intronic               11p15.1c    A              0.0300    −18.894                  99.9             0.00200

  rs1605987    EDIL3                            intergenic             5q14.3b     T              0.1921    −14.930                  98.2             0.00204

  rs3802292    CSMD1                            intronic               8p23.2d     T              0.3660    −15.587                  99.8             0.00238

  rs2273635    KIAA1305                         intronic               14q12a      T              0.0956    13.632                   97.8             0.00243

  rs7102454    CFL1, OVOL1, SNX32               intronic               11q13.1d    C              0.3163    −13.331                  96.8             0.00299

  rs2725795    C15ORF53                         intergenic             15q14d      G              0.0710    17.092                   99.2             0.00323

  rs2280732    PLB1                             intergenic             2p23.2b     C              0.2716    11.855                   97.2             0.00324

  rs3025365    DBH, FAM163B                     intergenic             9q34.2a     C              0.1761    11.904                   95.1             0.00326

  rs6979515    NXPH1                            intergenic             7p21.3d     G              0.3828    −18.242                  99.2             0.00364

  rs12332121   RPS17P2                          intronic               5q23.1a     C              0.1237    −15.236                  98.4             0.00445

  rs10046269   EYA4, TCF21                      intergenic             6q23.2c     C              0.0454    17.753                   99.4             0.00484

  rs4921144    MIR146A, ATP10B                  Upstream (5000 bp)     5q33.3d     A              0.0454    −12.473                  96.4             0.00495

  rs888053     VIT, STRN                        intronic               2p22.2b     A              0.2656    14.279                   96.5             0.00512

  rs1079082    ZNF579, FIZ1                     intronic               19q13.42c   T              0.1132    13.545                   96.4             0.00589

  rs4531650    EGLN3, C14ORF147                 intronic               14q13.1c    C              0.3818    −14.878                  98.3             0.00643

  rs1799884    GCK, YKT6                        intergenic             7p13d       A              0.1892    −11.829                  96.7             0.00724
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ MAF stands for Minor allele frequency; ^b^ Effect size obtained from top 4000 SNPs; ^c^ BSS in top 4000 SNPs; ^d^ *p*-values from multiple regression.

The predictive power of the 2239 SNPs identified from the top 4000 SNPs was next investigated. SNPs were ranked in order form smallest to largest and selected using a given BSS cut-off value, 0.95. Then, a multiple regression model with the selected SNPs was fitted to compute the corresponding adjusted *R*^2^ value. [Figure 3](#ijms-15-12407-f003){ref-type="fig"} compares the adjusted *R*^2^ values *versus* number of SNPs between the multiple SNP analysis and the single-marker approach. It is clear that the predictive power increases with the number SNP for both approaches, but the multi-stage approach always performs better than the single-marker approach for prediction purpose. This shows that multi-stage approach using a BSS cut-off value provides a better explanation of phenotype than the single marker approach.

![Phenotype variation between multi-stage approach (solid line) and single-marker approach (dashed line).](ijms-15-12407-g003){#ijms-15-12407-f003}

2.2. Discussion
---------------

The present study investigated genetic factors associated with PA for the Korean population, by performing large-scale GWA through single-SNP analysis and multiple SNP analysis via the EN regularization method. Single-SNP association tests are appropriate to determine individual associations between each SNP and the trait or phenotype. However, if the purpose is to predict the phenotype, then the joint identification of genetic factors would be powerful and provide a better prediction of the trait when multiple genetic factors exist for a common complex trait. In the presence of multicollinearity due to linkage disequilibrium among SNPs, EN regularization with BSS offers more accurate identification of multiple SNPs than ordinary multiple regression analysis.

Our single-marker analysis results showed that, although the most significant SNP did not attain the genome-wide significance level (rs7023003, *p*-value = 4.67 × 10^−6^), 41 SNPs did exhibit some evidence of association with PA at a less stringent significance level (*p*-value \< 10^−4^). Among the 27 genes identified, *CDKAL1*, CDK5 regulatory subunit associated protein 1-like 1, is one of the tailfloated protein family and associated with a type 2 diabetes susceptibility gene responsible for tRNALys modification \[[@B16-ijms-15-12407]\]. *CDKAL1* explores the TCR40/Get3 assisted pathway for insertion of its *C*-terminal transmembrane domain into the endoplasmic reticulum \[[@B16-ijms-15-12407]\]. It has been reported that this gene can influence insulin response and risk of type 2 diabetes \[[@B17-ijms-15-12407]\].

*TFPI2*, tissue factor pathway inhibitor 2, is found to be a tumor suppressor gene and frequently inactivated through promoter methylation in several kinds of tumors \[[@B18-ijms-15-12407]\]. In particular *TFPI2* methylation plays a key role in the diagnosis of colorectal cancer and has been demonstrated to exist in colorectal cancer patients' sera \[[@B19-ijms-15-12407]\].

*CCHCR1*, also called coiled-coil alpha-helical rod protein 1, is a candidate gene for Psoriasis which is one kinds of chronic inflammatory skin disorder \[[@B20-ijms-15-12407]\]. *CCHCR1* gene is found to be expressed in psoriatic lesions compared to normal healthy skin or other hyper proliferative skin disorders \[[@B21-ijms-15-12407],[@B22-ijms-15-12407]\]. *CCHCR1* has been demonstrated to be involved in steroidogenesis of the skin \[[@B20-ijms-15-12407]\].

Another gene, *RHOBTB1*, encodes Rho-related BTB domain-containing protein 1 \[[@B23-ijms-15-12407]\]. The protein encoded by this gene belongs to the Rho family of the small GTPase superfamily. It has a GTPase domain, a proline-rich region, a tandem of 2 BTB (broad complex, tramtrack, and bric-a-brac) domains, and a conserved *C*-terminal region. The protein plays a role in small GTPase-mediated signal transduction and the organization of the actin filament system. Alternate transcriptional splice variants have been characterized. It is known that the gene is highly expressed in skeletal muscle, stomach, placenta, kidney, and testis.

The single-marker analysis also identified *ASTN2*. It encodes a protein that is expressed in the brain and may function in neuronal migration, based on functional studies of the related *astrotactin 1* gene in human and mouse. A deletion at this locus was shown to be associated with schizophrenia \[[@B24-ijms-15-12407]\]. Multiple transcript variants encoding different proteins have been identified in this locus.

Through the multi-stage approach, subsets of multiple SNPs were jointly identified through the EN regularization method. Among the 457 common SNPs found, 59 SNPs with BSS values exceeding 0.95 were mapped to 76 genes. Of these genes, *ADAM12* encodes ADAM metallopeptidase domain 12 and is a disintegrin and metalloproteases family member \[[@B25-ijms-15-12407]\]. *ADAM12* is also a multidomain type I transmembrane protein that functions both in normal physiology and in diseases \[[@B25-ijms-15-12407]\]. *CCNI* gene, cyclin I, is also identified. *CCNI* is known to be expressed in human forebrain cortex \[[@B26-ijms-15-12407]\]. *CCNI* is also presented in skeletal muscle, heart, and brain and expressed constantly during cell cycle progression \[[@B26-ijms-15-12407]\]. Moreover, *PTPN5* encodes protein tyrosine phosphatase, non-receptor type 5 and involves in regulating the occurrence of abnormal stress responses underlying depression-related disorders \[[@B27-ijms-15-12407]\]. The basal levels of *PTPN5* expression in the dorsal hippocampus determine an individual's susceptibility for developing stress-related cognitive and morphological changes \[[@B27-ijms-15-12407]\]. Another gene found, *NRXN3* (neurexin 3), is a member of the neuroxines protein family that acts in the vertebrate nervous system as cell adhesion molecules and receptors \[[@B28-ijms-15-12407]\]. The mutations of *NRXN3* are related to alcohol and nicotine dependence in patients who suffer from schizophrenia \[[@B29-ijms-15-12407],[@B30-ijms-15-12407]\].

Pathway analysis of the 59 SNPs led to the identification of MODY. Its inherence is responsible for non-insulin-dependent diabetes typically diagnosed among young people, especially under 25 years of age \[[@B31-ijms-15-12407],[@B32-ijms-15-12407]\]. MODY is often referred to as monogenic diabetes, which is thought to be different from type 1 and type 2 diabetes \[[@B33-ijms-15-12407],[@B34-ijms-15-12407]\]. MODY is also known to include the *GCK* gene and the *HES1* gene. The gene *GCK*, glucokinase, is one of the frequently causing MODY genes and accounts for approximately 35% of cases \[[@B33-ijms-15-12407]\]. *HES1*, Hairy enhancer of split 1, is one of the highly conversed family of Hairy related basic helix-loop-helix (bHLH) proteins \[[@B35-ijms-15-12407]\]. *HES1* is also known to be involved specifically in Notch1 signaling in neural cells and in bone narrow \[[@B35-ijms-15-12407]\].

The main limitation of our study concerns the self-reporting nature of PA and the questions used were not sufficiently detailed. In addition to possible recall error by the participants, the phenotypes of total PA level may not be well defined. PA was classified by five categories based on MET intensities with average MET assigned to each category. The estimated total PA level may dilute MET intensities and lead to a low power for the genetic association study. Furthermore, it is not feasible to compare our results with previous studies in the absence of similar genotyped SNPs. Consequently, we adopted the bootstrap sampling scheme to obtain replication data sets with appropriate selection stability measure to confirm the findings \[[@B11-ijms-15-12407]\].

3. Experimental Section
=======================

3.1. Subjects
-------------

Study subjects were selected from an ongoing population-based cohort, as part of the Korean Genome and Epidemiology Study (KoGES). Participants were recruited from residents in two cities (Ansung and Ansan) in Gyeonggi-do, Korea. We enrolled 10,038 males and females between 2001--2002 for a baseline study, whose demographics have been reported \[[@B8-ijms-15-12407]\]. The Korean Genome and Epidemiology Study was launched in 2007, whereby over 10,000 subjects were recruited from two community-based cohorts: the rural Ansung and urban Ansan cohorts in the Gyeonggi of Korea. The initial samples included 5018 and 5020 participants aged 40 to 69 years from the two cohorts, respectively \[[@B36-ijms-15-12407]\]. [Table 3](#ijms-15-12407-t003){ref-type="table"} summarizes the demographic characteristics of the participants. There were more female participants in Ansung than Ansan but the Ansung cohort was on average older than the Ansan cohort, reflecting the differences between rural and urban areas. This study obtained approval from the appropriate institutional review boards of each participating institution, and written informed consent was obtained from all participants.
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###### 

Demographic characteristics of participants in the Korean cohorts.

  Cohort               Sex (*n*)   Age (Mean ± SD)                                        
  -------------------- ----------- ----------------- ------ -------------- -------------- --------------
  **Ansung (rural)**   1658        2240              3898   55.92 ± 8.66   55.65 ± 8.81   55.77 ± 8.75
  **Ansan (urban)**    2337        2219              4556   48.56 ± 7.44   49.60 ± 8.22   49.07 ± 7.85
  **Total**            3995        4459              8454   51.61 ± 7.44   52.64 ± 9.04   52.16 ± 8.92

3.2. Physical Activity Information
----------------------------------

Information on intensity and duration of daily PA was obtained from each participant using a structured questionnaire that included five components on PA: stable (lying down except sleeping), sitting (e.g., during typing, playing cards, driving, office work, attending a class), low intensity (e.g., walking, doing the laundry, cleaning, leisure time ping pong), medium intensity (e.g., walking, carpentering, regular exercise, badminton, swimming, tennis), high intensity (e.g., sports competition, climbing, running, logging, farming). For each type of PA, its duration was measured in minutes. Since each question contained multiple PAs with varying MET intensities, the average MET intensity was assigned. The total amount of daily PA was then calculated by summing across the products of the average MET and the corresponding durations \[[@B37-ijms-15-12407]\].

3.3. Genotypes
--------------

Genomic DNA samples were isolated from peripheral blood drawn from the participants. The majority of genomic DNAs were genotyped on the Affymetrix Genome-Wide Human SNP array 5.0 containing 500,568 SNPs. From the total of 10,038 participants, 10,004 available samples were genotyped \[[@B36-ijms-15-12407]\] by implementing Bayesian robust linear modeling with the Mahalanobis distance (BRLMM) algorithm, and standard quality control procedures were adopted. Samples with high missing genotype call rate (\>4%, *n* = 401), high heterozygosity (\>30%, *n* = 11), gender inconsistencies (*n* = 41), and those obtained from individuals who had developed any form of cancer (*n* = 101), were excluded from subsequent analyses, along with related or identical individuals whose computed average pairwise identity-by-state value was higher than that estimated from first-degree relatives of Korean sib-pair samples (\>0.80, *n* = 601). Samples whose genotype-inferred sex disagreed with clinical records were re-tested for sex confirmation using the SNaPshot Multiplex System (Applied Biosystems, Life Technologies, Carlsbad, CA, USA). Markers with high missing gene call rate (\>5%), low Minor Allele Frequency (MAF) (\<0.01) and significant deviation from Hardy-Weinberg equilibrium (*p*-value \< 1 × 10^−6^) were excluded, leaving a total of 352,228 markers to be examined among 8842 individuals. For multiple SNP analysis, reduced information was common due to missing values. To get complete genotype data, we imputed missing genotypes using the Fastphase software (University of Washington, Seattle, WA, USA) \[[@B38-ijms-15-12407]\]. As a result, a total of 344,893 SNP markers with chromosomes 1--22 were obtained for our study.

3.4. Statistical Analysis
-------------------------

Single-SNP association analysis was first performed for each of the 344,893 SNPs using linear regression analysis with adjustments for sex, age, area, and body mass index. A multi-stage approach \[[@B11-ijms-15-12407]\] was next conducted to identify multiple SNPs associated with PA. At the first stage, through single-SNP analysis, we selected the top 1000, top 2000, top 3000, and top 4000 SNPs which exhibit strong associations with PA for dimensional reduction. At the second stage, multiple-SNP analysis was performed with the EN regularization method, by utilizing a subset of SNPs chosen at the first stage. At the final stage, the bootstrap selection stability (BSS) measure was computed for each SNP, which indicated how consistently a SNP was replicated in bootstrap datasets. SNPs with high BSS values tend to have a higher chance of being replicated. More information about a multi-stage approach is described in Cho *et al.* \[[@B11-ijms-15-12407]\].

To investigate the biological significance of PA-related genetic variants, we mapped the identified SNPs to an exon/intron and performed pathway enrichment analysis. All pathways related to the identified genes were investigated via the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Pathways were evaluated by the over-representation statistic and the Expression Analysis Systematic Explorer (EASE, Database for Annotation, Visualization and Integrated Discovery (DAVID), Frederick, MD, USA) score \[[@B39-ijms-15-12407]\]. EASE calculates over--representation using Fisher's exact probability with respect to the total number of genes assayed and annotated within each system to measure the gene-enrichment in annotation terms \[[@B39-ijms-15-12407]\]. *p*-values less than 0.1 defined as significantly regulated pathway. The single-marker association tests and adopted multi-stage approach were conducted using the PLINK \[[@B40-ijms-15-12407]\] and R \[[@B41-ijms-15-12407]\] software.

4. Conclusions
==============

In this study, we demonstrated that the joint identification of SNPs could enable the identification of multiple SNPs with good predictive power for PA and a pathway enriched for PA. Previous genetic studies have focused on the relationship between PA and health (or fitness) \[[@B37-ijms-15-12407],[@B42-ijms-15-12407],[@B43-ijms-15-12407],[@B44-ijms-15-12407]\]. Future studies are recommended to determine pertinent genetic factors that influence health- or fitness-related PA. In view of the large population diversities in GWA studies, a systematic comparison is needed between our Korean results and those derived from other populations.
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